JNJ-63723283
JNJ-63723283 Uses, Dosage, Side Effects, Food Interaction and all others data.
JNJ-63723283 is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers).
| Trade Name | JNJ-63723283 |
| Generic | Cetrelimab |
| Cetrelimab Other Names | Cetrelimab, JNJ-63723283 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here JNJ-63723283
